Greentown Labs names new CEO to lead pioneering climate tech incubator

Transition News

Georgina Campbell Flatter worked closely with Greentown Labs when it was founded in 2011 and now will lead the incubator as CEO. Photo courtesy Greentown Labs

Houston and Boston climate tech incubator Greentown Labs has named Georgina Campbell Flatter as the organization’s incoming CEO.

Flatter will transition to Greentown from her role as co-founder and executive director of TomorrowNow.org, a global nonprofit that studies and connects next-generation weather and climate technologies with communities most affected by climate change.

“We are at a transformational moment in the energy transition, with an unprecedented opportunity to drive solutions in energy production, sustainability, and climate resilience,” Flatter said in a news release. “Greentown Labs is, and has always been, a home for entrepreneurs and a powerhouse of collaboration and innovation.”

Previously, Flatter worked to launch TomorrowNow out of tomorrow.io, a Boston-based AI-powered weather intelligence and satellite technology company. The organization secured millions in climate philanthropy from partners, including the Gates Foundation, which helped deliver cutting-edge climate solutions to millions of African farmers weekly.

Flatter also spent 10 years at the Massachusetts Institute of Technology (MIT), where she was a senior lecturer and led global initiatives at the intersection of technology and social impact. Her research work includes time at Langer Lab and Sun Catalytix, an MIT – ARPA-E-funded spin-out that focused on energy storage solutions inspired by natural photosynthesis. Flatter is also an Acumen Rockefeller Global Food Systems Fellow and was closely involved with Greentown Labs when it was founded in Boston in 2011, according to the release.

“It’s rare to find an individual who has impressive climate and energy expertise along with nonprofit and entrepreneurial leadership—we’re fortunate Georgie brings all of this and more to Greentown Labs,” Bobby Tudor, Greentown Labs Board Chair and Chairman of the Houston Energy Transition Initiative, said in a news release.

Flatter will collaborate with Kevin Dutt, Greentown’s Interim CEO, and also continue to serve on Greentown’s Board of Directors, which was recently announced in December and contributed to a successful $4 million funding round. She’s also slated to speak at CERAWeek next month.

“In this next chapter, I’m excited to build on our entrepreneurial roots and the strength of our ever-growing communities in Boston and Houston,” Flatter added in a news release. “Together, we will unite entrepreneurs, partners, and resources to tackle frontier challenges and scale breakthrough technologies.”

Greentown also named Naheed Malik its new chief financial officer last month. The announcements come after Greentown’s former CEO and president, Kevin Knobloch, announced that he would step down in July 2024 after less than a year in the role.

---

This article originally appeared on our sister site, EnergyCapital.

From Your Site Articles
Kanin Energy set up shop in Greentown Labs last year to grow its impact on the energy transition. Photo via Getty Images

Why this energy transition startup came to Houston to grow, build its waste-heat-to-power tech

eyes on hou

Waste heat is everywhere, but in Houston, the Energy Capital of the World, it is becoming a hot commodity. What is it? Janice Tran, CEO of Kanin Energy, uses the example of turning ore into steel.

“There’s a lot of heat involved in that chemical process,” she says. “It’s a waste of energy.”

But Kanin Energy can do something about that. Its waste-heat-to-power, or WHP, concept uses a technology called organic rankine cycle. Tran explains that heat drives a turbine that generates electricity.

“It’s a very similar concept to a steam engine,” she says. Tran adds that the best term for what Kanin Energy does is “waste heat recovery.”

Emission-free power should be its own virtuous goal, but for companies creating waste heat, it can be an expensive endeavor both in terms of capital and human resources to work on energy transition solutions. But Kanin Energy helps companies to decarbonize with no cost to them.

“We can pay for the projects, then we pay the customers for that heat. We turn a waste product into a revenue stream for our customer,” Tran explains. Kanin Energy then sells the clean power back to the facility or to the grid, hence decarbonizing the facility gratis. Financing, construction, and operations are all part of the package.

Kanin Energy began at the height of the COVID-19 pandemic, in the spring of 2020.

“We started like a lotus. A lotus grows in mud — you start in the worst conditions and everything is better and easier from there,” says Tran.

That tough birth has helped provide the team with a discipline and thoughtfulness that’s been key to the company’s culture. Remote work has forced the team to get procedures clearly in place and react efficiently.

Back in May of 2020, its inception took place in Calgary. But the team, which also includes CDO Dan Fipke and CTO Jake Bainbridge, began to notice that many of their customers were either based in Houston or had Houston ties.

A year ago, the Kanin team visited Houston to see if the city could be a fit for an office. In July of 2022, Tran opened Kanin Energy offices in Greentown Labs.

“We’re hiring and building our team office out of Greentown. It’s been really great for us,” she says.

With the company now in its commercialization stage, Tran says that becoming part of the Houston energy ecosystem has been invaluable for Kanin.

The investments being made in climate tech and in energy transition make Space City the right place for the company. For Canadian-born Kanin Energy, Houston is now home. Investors across the nation, including Texas, are now helping Kanin to blossom, much like the lotus.

Janice Tran is the CEO and co-founder of Kanin Energy. Photo via LinkedIn

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings